Fed-batch production of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in soluble form in Escherichia coli and its purification and characterization

Wiley, 1995, Identification and characterization of a new member of the TNF family that induces apoptosis, Immunity, 3, 673, 10.1016/1074-7613(95)90057-8 Kruyt, 2008, TRAIL and cancer therapy, Cancer Lett., 263, 14, 10.1016/j.canlet.2008.02.003 Lim, 2015, Targeting TRAIL in the treatment of cancer: new developments, Expert. Opin. Ther. Targets, 19, 1171, 10.1517/14728222.2015.1049838 Hymowitz, 2000, A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL, Biochemistry, 39, 633, 10.1021/bi992242l Ashkenazi, 1999, Safety and antitumor activity of recombinant soluble Apo2 ligand, J. Clin. Investig., 104, 155, 10.1172/JCI6926 Daniel, 2001, The kiss of death: promises and failures of death receptors and ligands in cancer therapy, Leukemia, 15, 1022, 10.1038/sj.leu.2402169 Soria, 2011, Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer, J. Clin. Oncol., 29, 4442, 10.1200/JCO.2011.37.2623 Lemke, 2014, Getting TRAIL back on track for cancer therapy, Cell Death. Differ., 21, 1350, 10.1038/cdd.2014.81 Bao, 2016, Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations, Cell Oncol. (Dordr), 10.1007/s13402-016-0278-4 Dai, 2015, Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy, Exp. Biol. Med. (Maywood), 240, 760, 10.1177/1535370215579167 Lin, 2007, Expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), Protein Expr. Purif., 51, 276, 10.1016/j.pep.2006.07.026 Wang, 2009, High-level expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), Appl. Biochem. Biotechnol., 157, 1, 10.1007/s12010-007-8079-x Kang, 2007, Refolding and structural characteristic of TRAIL/Apo2L inclusion bodies from different specific growth rates of recombinant Escherichia coli, Biotechnol. Prog., 23, 286, 10.1021/bp060238c Sun, 2006, Improvement of expression level and bioactivity of soluble tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) by a novel zinc ion feeding strategy, Biotechnol. Lett., 28, 1215, 10.1007/s10529-006-9073-z Luo, 2006, Optimization of culture on the overproduction of TRAIL in high-cell-density culture by recombinant Escherichia coli, Appl. Microbiol. Biotechnol., 71, 184, 10.1007/s00253-005-0131-6 Jeong, 1999, High-level production of human leptin by fed-batch cultivation of recombinant Escherichia coli and its purification, Appl. Environ. Microbiol., 65, 3027, 10.1128/AEM.65.7.3027-3032.1999 Nguyen, 2008, Studying on high density cell cultivation of E. coli BL21(DE3)/pET43Ins by fed-batch, J. Biotechnol., 136, S516, 10.1016/j.jbiotec.2008.07.650 Cui, 2007, Efficient preparation of an acyclic permutant of kalata B1 from a recombinant fusion protein with thioredoxin, J. Biotechnol., 130, 378, 10.1016/j.jbiotec.2007.05.006 Kim, 1996, Efficient fixation procedure of human leukemia cells in sulforhodamine B cytotoxicity assay, J. Pharmacol. Toxicol. Methods, 36, 163, 10.1016/S1056-8719(96)00113-X Luli, 1990, Comparison of growth, acetate production, and acetate inhibition of Escherichia coli strains in batch and fed-batch fermentations, Appl. Environ. Microbiol., 56, 1004, 10.1128/aem.56.4.1004-1011.1990 Shen, 2004, High-level production of soluble tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in high-density cultivation of recombinant Escherichia coli using a combined feeding strategy, Biotechnol. Lett., 26, 981, 10.1023/B:BILE.0000030043.84226.ac Paul, 2008, Chaperone mediated solubilization of 69-kDa recombinant maltodextrin glucosidase in Escherichia coli, J. Appl. Microbiol., 104, 35 Turner, 2005, Optimized expression of soluble cyclomaltodextrinase of thermophilic origin in Escherichia coli by using a soluble fusion-tag and by tuning of inducer concentration, Protein Expr. Purif., 39, 54, 10.1016/j.pep.2004.09.012 Mhatre, 1995, Purification of antibody Fab fragments by cation-exchange chromatography and pH gradient elution, J. Chromatogr. A, 707, 225, 10.1016/0021-9673(95)00319-I Nam, 2002, Association of human tumor necrosis factor-related apoptosis inducing ligand with membrane upon acidification, Eur. J. Biochem., 269, 5280, 10.1046/j.1432-1033.2002.03242.x Lawrence, 2001, Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions, Nat. Med., 7, 383, 10.1038/86397 Cha, 1999, Expression, purification and crystallization of recombinant human TRAIL, Acta Crystallogr. D., 55, 1101, 10.1107/S090744499900164X Wang, 2004, Chemotherapeutic drugs enhanced rsTRAIL tumoricidal activity, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 26, 524